logo

Merck & Co Inc. (MRK)



Trade MRK now with
  Date
  Headline
3/5/2019 7:01:20 AM Merck Begins Cash Tender Offer To Purchase Immune Design
3/4/2019 6:48:33 AM Merck Says EMA Adopts Positive Opinion For KEYTRUDA Anti-PD-1 Therapy
2/21/2019 6:47:54 AM Merck To Acquire Immune Design For $5.85/Shr Cash
2/20/2019 6:48:05 AM FDA Grants Priority Review To Merck's SBLA For KEYTRUDA Monotherapy
2/15/2019 7:01:28 AM Merck: FDA Grants Priority Review To Its Supplemental BLA For KEYTRUDA With Inlyta For Advanced RCC
2/14/2019 6:48:33 AM Merck To Present Data From Three Cohorts Of Phase 1b/2 KEYNOTE-365 Study
2/5/2019 6:47:14 AM Merck: FDA Accepts For NDA Review For Combination Of Imipenem/Cilastatin And Relebactam, And SNDA For ZERBAXA
2/4/2019 6:46:45 AM Merck Says CHMP Of EMA Adopted Positive Opinion Recommending KEYTRUDA In Combination With Chemotherapy